Revenue Increased 16% Year-Over-Year Gross Profit Increased 45% Year-Over-Year RICHLAND, WASHINGTON – February 11, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options...
Bundled Treatment Program Provides New Opportunities For Treating Physicians and Patients Facing Limited Options RICHLAND, WASHINGTON – February 5, 2020 – Isoray, Inc. (NYSE American: ISR) today announced an executed agreement with MIM Software to deliver a novel...
While brachytherapy continues to demonstrate positive outcomes with swift side effect resolution for prostate cancer treatment, the modality remains underutilized. In this episode, Dr. John Sylvester is joined by radiation oncologist Dr. Alex Hsi to discuss why the...
Conference Call is Tuesday, February 11, 2020 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – January 31, 2020– Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the...
Patients with Newly Diagnosed Malignant Brain Tumors Now Eligible for Surgically Targeted Radiation Therapy TEMPE, Ariz. — GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced that the U.S. Food...
Welcome to the Isoray Prostate Cancer Connect Podcast! In each episode of the new podcast series, Dr. John Sylvester and featured guests will talk in-depth about the current status and advancements in brachytherapy for prostate cancer treatment. In this episode, Dr....
Welcome to the Isoray’s Prostate Cancer Connect Podcast! Each episode of the new podcast series, Dr. John Sylvester and featured guests will be talking in-depth about the current status and advancements in brachytherapy for prostate cancer treatment. Dr. John...
Record Revenue and Gross Profit Revenue Increased 48% Year-Over-Year RICHLAND, WASHINGTON – November 12, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the...
Conference Call is Tuesday, November 12, 2019 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – October 31, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout...
RICHLAND, WASHINGTON – October 29, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR) announced today that it will demonstrate its latest products at the American Brachytherapy Society’s (ABS) annual prostate brachytherapy workshop. The workshop is scheduled to take place...
